Brief: Elicio To Merge With A Wholly-Owned Unit Of Angion In An All-Stock Transaction

Elicio Therapeutics

17/01/2023 10:11

Jan 17 (Reuters) - Angion Biomedica Corp  ANGN.O :
    * ANGION- MERGER TO RESULT IN NASDAQ-LISTED CO FOCUSED ON
DEVELOPING IMMUNOTHERAPIES BASED ON ELICIO'S LYMPH
NODE-TARGETING AMPHIPHILE (CORRECTS SOURCE)
    * ELICIO THERAPEUTICS AND ANGION ENTER INTO DEFINITIVE
MERGER
AGREEMENT
    * ELICIO WILL MERGE WITH A WHOLLY-OWNED UNIT OF ANGION IN AN
ALL-STOCK TRANSACTION
    * ANGION - CURRENT ANGION STOCKHOLDERS ARE EXPECTED TO OWN
34.5%
OF NEWLY COMBINED COMPANY WHILE ELICIO STOCKHOLDERS WILL OWN
65.5% OF NEWLY COMBINED CO.

Source text for Eikon: [ID: nGNX38fS41]
Further company coverage:  ANGN.O 
 ((Reuters.Briefs@thomsonreuters.com;))